Key Takeaways
- A quarter defined by deferral, not destruction: Revenue fell to Rs. 319 crores and EBITDA to Rs. 8 crores as a US FDA warning letter forced an Rs. 80+ crore sales deferral from September into October, but no customer cancelled a single order.
- The warning letter is a timing problem, not a terminal one: Mature products are unaffected, new molecules can be routed to the Panoli site, and remediation is on track for completion by December 2025, with re-inspection expected around March-May 2026.
- Crop protection remains a persistent drag: The segment posted negative EBIT and has yielded virtually no profit contribution for five years, though volumes are beginning to recover and the company is rationalizing assets toward specialty chemicals.
- The CDMO pipeline is filling, but revenue is years away: Early-stage RFP activity is sharp, a high-potency lab is now operational, and a large plant is being repurposed for pharma, yet major revenue from these bets is not expected until FY28.
- What to watch next quarter: Whether the deferred Rs. 80+ crores actually converts to recognized revenue in Q3, the pace of customer risk-assessment clearances, and any tangible progress on the FDA re-inspection timeline.
The Warning Letter: Impact, Remediation & Customer Response
- What triggered the disruption: The Bangalore facility received OAI status in May 2025, followed by a warning letter in August 2025. This temporarily delayed off-take across generics and CDMO businesses as customers conducted internal risk assessments before resuming supply.
- Deferral mechanics: Rs. 80+ crores of sales were reversed in September because customers asked to hold material pending risk assessment. Those sales were subsequently completed in the first few weeks of October, representing a shift of roughly one month or 15 days.
- No cancellations, only pauses: Not a single customer cancelled orders. Purchase orders in the system remain intact; customers asked to pause, re-evaluated risk post-warning letter, were satisfied, and shipments restarted from October.
- Mature products insulated: The warning letter does not bar existing business. Mature approved products continue to move, and volume is expected to return in H2 for these products.
- New molecule workaround: New molecules can be routed to the Panoli site, which was approved by the US FDA for APIs in May 2023. The company is now filing DMFs from Panoli because the OAI status at Bangalore has not yet been lifted.
- Cost of compliance: Rs. 8-10 crores in fixed costs were added for US-based GMP consultants, plus investments in plant upgrades. Management time and resources are heavily consumed by remediation efforts. Two global remediation partners have been onboarded to strengthen internal quality systems.
- Market scope of restriction: Only the US market is affected. Other approvals across Latin America, Mexico, and Japan remain intact. Management explicitly ruled out supplying through a European arm to indirectly reach the US market, stating the route would not work for new ANDA filings.
- Re-inspection timeline: February is seen as the right time to approach the US FDA. If the agency is convinced of readiness, re-inspection is expected around March, April, or May 2026, though management acknowledges there are always uncertainties.
Manoj Mehrotra: "February is the right time to really approach them. And then if they believe that we are ready and we are able to convince them, then they come for a re-inspection. So, we will expect in maybe March, April, May, they should come for a re-inspection."
Pharmaceutical Business: CDMO, API & Animal Health
- CDMO demand signals: A sharp uptake in early-stage RFPs is underway, particularly in high-value small molecules and advanced intermediates, driven by global innovators and emerging biotech firms diversifying away from single-region dependencies. Several projects are transitioning from early development to pilot scale.
- R&D positioning: Hikal focuses on manufacturing-led R&D, engaging post-Phase 1 or early Phase 2 where process and manufacturing know-how is key. Within months, kilogram quantities are delivered; within six months, tens of kilograms; launch follows within one to two years after filings. This makes customer relationships sticky.
- RFP conversion and BD build-out: Pharma RFP conversion rate is 15-20%, with six to twelve months to convert. A business development person was hired on the US West Coast targeting mid-size and biotech companies, and another in Europe for mid-size and large customers. One breakthrough customer has been achieved, and a second is on the way. Management expects to improve the conversion ratio to 20-25% as market familiarity and cost-competitiveness increase.
- Development revenue: Around $4 to $5 million of development revenue is expected this year from new customers.
- High-potency laboratory: A state-of-the-art high-potency lab was inaugurated in Q2, enabling entry into oncology APIs and high-potency peptides. The company is also exploring HPAPIs, ADCs, linkers, and peptides, though not fermentation. Commercial supplies from this lab will take two to three years to materialize; initially, only development revenue will flow from small and innovator companies.
- Pilot scale investment: Investment is underway in pilot scale capacity at the Pune R&D center to support key starting materials that have advanced into Phase III clinical trials, with commercial launch anticipated in FY27.
- Animal health progress: Most molecules under long-term supply agreements are now being delivered at small commercial volumes as registrations have come through across global markets. New development contracts were awarded for two molecules from global innovators, and proposals were submitted for two new RFPs from different global innovators for on-patent proprietary products.
- Animal health to human health cross-sell: Active discussions are underway with a large pharma player that is also an animal health customer, aiming to extend the relationship to the human health side, with a goal of starting at least some business over the next couple of years.
- API business resilience: The API business continued to penetrate key markets, supported by an established portfolio and expanding market share in select molecules, reducing dependence on regulated markets and improving resilience against US tariff uncertainties.
Sameer Hiremath: "No, I don't think, see, we are not catering to the basic contract research type of discovery. We are focusing on manufacturing led R&D, which is typically post-Phase 1. Late Phase 1, early Phase 2 is where we are getting involved in molecules."
Crop Protection & Specialty Chemicals
- Crop protection performance: Revenue stood at Rs. 129 crores with EBIT of minus Rs. 10 crores. Margins remain under pressure from ongoing pricing challenges driven by oversupply in the global market, though volumes have started to recover. One analyst noted the segment has yielded virtually no profit contribution over the last five years.
- Gradual recovery expected: Management anticipates a gradual recovery in the second half of the year, with stable performance expected on a full-year basis, similar to last year.
- Strategic pivot to specialty chemicals: The company is rationalizing crop assets and retooling some plants for specialty chemicals, targeting niche, medium-volume, high-complexity molecules for personal care, specifically skincare, with GMP manufacturing. The intent is explicitly not to pursue low-end, low-margin, commodity, large-volume products.
- Personal care commercialization: Two to three products are expected to be commercialized in the second half of this financial year, with volumes ramping up in the next financial year. A new set of FMCG and cosmetic customers have visited, samples have been approved, and seeding has occurred over the last six to nine months. The plant will be commercialized by the end of Q4, with dispatches starting from the next financial year.
- Crop protection CDMO R&D: Crop protection companies are now under cost pressure. R&D was not historically outsourced to India, but Hikal is pursuing joint development projects with customers. The NCE pipeline in the Pune R&D center has increased substantially over the last two to three years.
Sameer Hiremath: "I think that is going to be the differentiator for Hikal. And we are not trying to do the low-end, low-margin, commodity, large-volume. It is niche, medium-volume type of molecules for skincare products."
Capacity Build-Out & Asset Repurposing
- Plant repurposement: A very large asset is being repurposed entirely into pharma, executed in phases. Phase 1 will be completed by the end of this financial year (Q4), and Phase 2 by the end of the calendar year. Revenue is expected to start from the next financial year, with major revenue arriving from FY28 onwards.
- Dual filing strategy: The company is now dual filing for all products between Jigani and Panoli, creating capacity in Panoli for new molecules being filed this year and progressing toward dual-side validation for all critical APIs as part of risk mitigation.
- Pune site expansion: The Pune site is being expanded for high-potent API manufacturing and to house a pilot plant, which over the long term will provide further de-risking across sites.
- Food and nutraceutical ingredients: Operations are on track to scale, with peak output expected within the next 18 to 24 months.
- New kilo lab: A new kilo lab was commissioned at the specialty chemicals site, strengthening early-stage development and scale-up infrastructure.
- Manpower cost front-loading: Manpower costs increased due to new assets coming on stream from CAPEX and the onboarding of business development people in global markets.
Financials & Margin Walk
- Revenue and EBITDA: Consolidated revenue was Rs. 319 crores, with EBITDA at Rs. 8 crores. The pharmaceutical business contributed Rs. 190 crores in revenue with an EBIT margin of negative 9.2%, while crop protection delivered Rs. 129 crores with EBIT of minus Rs. 10 crores.
- Fixed cost under-absorption: The short-term deferral of sales in the pharmaceutical business, with orders executed toward the end of Q2 booked in October 2025, caused under-absorption of fixed costs.
- Full-year CAPEX guidance maintained: The company is maintaining its full-year CAPEX guidance of Rs. 200 crores.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FDA remediation plan completion | On track for completion | December 2025 |
| FDA re-inspection approach | Approach US FDA; re-inspection if convinced of readiness | Approach February 2026; re-inspection March-May 2026 |
| Pharma revenue recovery | Deferred Rs. 80+ crores recognized; deliveries ramp up significantly | H2 FY26 (Q3 and Q4) |
| FY26 pharma growth guidance | Still working toward double-digit growth target | FY26 |
| Crop protection recovery | Gradual recovery; stable full-year performance similar to last year | H2 FY26 |
| Personal care commercialization | Two to three products commercialized; plant commercialized by Q4; dispatches from next FY | H2 FY26 / Q4 FY26 |
| Development revenue from new customers | Around $4-5 million | FY26 |
| Key starting materials commercial launch | Commercial launch of Phase III-advanced materials | FY27 |
| Plant repurposement Phase 1 | Phase 1 complete | Q4 FY26 |
| Plant repurposement Phase 2 | Phase 2 complete | End of calendar year (2026) |
| Major revenue from repurposed plant | Revenue starts next FY; major revenue | FY28 onwards |
| High-potency lab commercial supplies | Commercial supplies begin | Two to three years (FY28-FY29) |
| Food and nutraceutical peak output | Reach peak output | Within 18-24 months |
| FY27 characterization | Transition year; growth expected to return | FY28 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated revenue | ₹319 cr, H1 FY26 at ₹699 cr |
| EBITDA | ₹8 cr, margin of 2.6%; H1 FY26 EBITDA ₹32 cr, margin 4.6% |
| Pharmaceutical segment revenue | ₹190 cr |
| Pharmaceutical segment EBIT | ₹(17) cr, margin negative 9.2% |
| Crop protection segment revenue | ₹129 cr |
| Crop protection segment EBIT | ₹(10) cr |
| Finance costs | ₹15 cr, down 13% YoY and 20% YoY |
| H1 FY26 capex | ₹65 cr, full-year guidance maintained at ₹200 cr |
| Debt-equity ratio | 0.55, improved from 0.59 at start of year |
| Revenue deferred to Q3 | ₹80+ cr, pharma sales reversed from September and booked in October |
| CDMO revenue share | ~50% of total revenue |
| Pharma RFP conversion ratio | 15–20%, expected to improve to 20–25% |
| Development revenue from new CDMO customers | $4–5 million expected in FY26 |
| Remediation fixed cost impact | ₹8–10 cr added for US-based GMP consultants |
| US FDA re-inspection timeline | March–May 2026 expected |